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ApoptosisPulmonary arterial hypertension (PAH) is characterized by pulmonary arterial remodeling mainly due to excess
cellular proliferation and apoptosis resistance of pulmonary arterial smooth muscle cells (PASMCs). Salidroside,
an active ingredient isolated from Rhodiola rosea is proposed to exert protective effects against PAH. However,
the function of salidroside in PAH has not been investigated systematically and the underlying mechanisms
are not clear. To investigate the effects of salidroside on PAH, the mice in chronic hypoxia model of PAH were
given by an increasing concentration of salidroside (0, 16 mg/kg, 32 mg/kg, and 64 mg/kg). After salidroside
treatment, the chronic hypoxia-induced right ventricular hypertrophy and pulmonary arterial remodeling
were attenuated, suggesting a protective role played by salidroside in PAH. To explore the potentialmechanisms,
the apoptosis of PASMCs after salidroside treatment under hypoxia conditions were determined in vivo and
in vitro, and also the mitochondria-dependent apoptosis factors, Bax, Bcl-2, cytochrome C, and caspase 9 were
examined. The results revealed that salidroside reversed hypoxia-induced cell apoptosis resistance at least par-
tially via a mitochondria-dependent pathway. In addition, salidroside upregulated the expression of adenosine
A2a receptor (A2aR) in lung tissues ofmice and in PASMCs in vitro after hypoxia exposure. Combined the evidence
above,we conclude that salidroside can attenuate chronic hypoxia-induced PAHby promoting PASMCs apoptosis
via an A2aR related mitochondria dependent pathway.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pulmonary arterial hypertension (PAH) is a subset of pulmonary hy-
pertensive syndromes and characterized by pulmonary arterial remod-
eling, leading to increased pulmonary vascular resistance and increased
pulmonary arterial pressure [1–3]. PAH is a debilitating disease and re-
sults ultimately in right ventricular failure and death. It is reported that
PAH appears approximately in 12–50 per million in adult people [4].
Chronic hypoxia-induced PAH is a common type of PAH,mainly second-
ary to disorders of the respiratory system, such as chronic obstructive
pulmonary disease (COPD), obstructive sleep apnea, interstitial lung
disease, and chronic mountain sickness in plateau residents. Pulmonaryn; PASMCs, pulmonary arterial
chronic obstructive pulmonary
MYH11, smoothmusclemyosin
CAP,mean carotidarterial pres-
zyxywlx@163.com (L. Wang).
. This is an open access article underarterial remodeling is mainly due to the abnormal growth, the excess
cellular proliferation, and the apoptosis resistance of smooth muscle
cells [5–7]. Therefore, inhibition of the cell proliferation or induction
of the cell apoptosis may be an efﬁcient therapeutic strategy for PAH.
Mitochondrial dysfunction and mitochondrial-dependent apoptotic
pathway has been identiﬁed to be involved in the pathogenesis of pul-
monary arterial hypertension and play a critical role in hypoxic apopto-
sis of PASMCs [8–12]. Themitochondria dependent pathway starts with
anapoptosis-regulatingprotein family exempliﬁedby Bcl-2 family, such
as pro-apoptotic Bax and anti-apoptotic Bcl-2 [13–15]. Pro-apoptotic
factor, Bax, can enhance cytochrome C release from mitochondria [13,
14]. And cytochrome C release into cytosol activates caspase 9 which
then activates caspase 3 to execute the apoptotic program [13,15].
Whereas, the anti-apoptotic molecule, Bcl-2, can inhibit the activation
of Bax and the release of cytochrome C, consequently inhibits cell apo-
ptosis [15]. Previous researches reveal that the increased Bax/Bcl-2
ratio can reﬂect the activation of caspase program and the induction
of apoptosis [16]. Mitochondria dependent apoptosis is suppressed in
hypoxic human PASMCs (HPASMCs) in vitro and in PASMCs from
patients and rats with PAH [17].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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member of Crassulaceae and a well-known herb used to relieve high al-
titude sickness and acute exacerbation of PAH [18]. Several experimen-
tal and clinical studies of salidroside have provide evidences for its
multiple pharmacological activities including anti-inﬂammation [19],
anti-oxidation [20], anti-stress, anti-cancer, and enhancing immune ef-
fects [18,21,22]. Recent studies indicate that salidroside can rescue mi-
tochondria dysfunction induced by stimuli in human umbilical vein
endothelial cells (HUVECs) [23], and also salidroside can block
platelet-derived growth factor-BB induced proliferation of PASMCs
[24], suggesting that salidroside may exert protective effects against
PAHvia rebalancing cell proliferation and apoptosis of pulmonary artery
cells. However, the function of salidroside in PAH has not been investi-
gated systematically and the underlying mechanisms are not clear.
In the present study, we explored the effects of salidroside on PAH
and pulmonary arterial remodeling with a mouse model of chronic
hypoxia-induced PAH and examined whether salidroside affects
hypoxia-induced cell apoptosis resistance both in vivo and in vitro. In
addition, the expression of adenosine A2a receptor was also determined
to verify the involvement of the receptor.
2. Materials and methods
2.1. Materials
Salidroside, A2aR agonist CGS-21680, collagenase type I, and 4′,6-
diamidino-2-phenylindole dihydrochloride (DAPI) were obtained
from Sigma (St Louis, MO, USA). Trizol, fetal bovine serums (FBS), pen-
icillin G, streptomycin, and Dulbecco's Modiﬁed Eagle Medium (DMEM,
high glucose) were obtained from Life Technologies (CA, USA). Sso Ad-
vanced SYBRGreen Supermixwas obtained fromBio-Rad (Hercules, CA,
USA). The rabbit antibodies against A2aR, Bax, smooth muscle myosin
heavy chain 11 (MYH11), andα-smoothmuscle actin (SMA) were pur-
chased from Abcam (Cambridge, UK). The rabbit antibodies against
GAPDH, cytochrome C, cleaved caspase 3, cleaved caspase 9, voltage-
dependent anion channel (VDCA, porin), and Bcl-2 were purchased
from Cell Signaling Technology (MA, USA). The goat antibodies against
Bax and Bcl-2 were purchased from Santa Cruz (CA, USA). Cell counting
kit-8 (CCK-8) and TIANScript ﬁrst strand cDNA synthesis kit were pur-
chased from Dojindo Laboratories (Kumamoto, Japan) and TIANGEN
BIOTECH (Beijing, China), respectively. SuperSignal (R) West Femto
Maximum Sensitivity Substrate and BCA Protein Assay kit were pur-
chased from Pierce (WI, USA). DAB kit and Polink-2 plus Polymer HRP
Detection System were purchased from ZSGB BIO (Beijing, China).
DyLight™ 488 Conjugated Goat anti-Mouse IgG (H + L) was obtained
from Thermo Fisher Scientiﬁc (Waltham, MA, USA). Peroxidase conju-
gated goat anti-rabbit immunoglobulin G (IgG)was obtained from Jack-
son ImmunoResearch Laboratories (PA, USA). Alexa Fluor 647 Donkey
anti-Goat IgG (H + L) Antibody, 555 Donkey Anti-Goat IgG (H + L),
and 488 Donkey Anti-Rabbit IgG (H + L) Antibody were purchased
from Molecular Probes (Eugene, OR, USA).
2.2. Experimental animals and chronic hypoxia model of PAH
Forty male BALB/C mice (12–14 week old, weight 22–25 g) were
purchased from Silaike Experimental Animal Technology (Shanghai,
China). Animal housing and experimental protocols were approved by
Wenzhou Medical University. The mice were given free access to food
and water and were maintained in a room with a 12:12 hour light–
dark cycle between 20 and 24 °C. The mice were randomly assigned to
ﬁve groups: normoxia group (N) (n= 8), hypoxia group (H) (n= 8),
hypoxia plus salidroside groups (16 mg/kg, 32 mg/kg and 64 mg/kg,
named by HS16, HS32, HS64, respectively) (n= 8). Intraperitoneal in-
jection was given half an hour before mice were put in hypoxia cham-
ber. The normoxia group was injected saline and exposed to room air
whereas the hypoxia group was exposed to 9%–11% O2 with the sameinjection. The hypoxia environment was established by a mixture of
room air and nitrogen in a closed chamber. The fractional concentration
of O2 was monitored and controlled by a detector automatically. The
hypoxia exposure lasted for four weeks.
2.3. Measurements of RV hypertrophy
At the end of the hypoxia exposure period, the mice were anesthe-
tized with 20% urethane (1 mL/100 g, intraperitoneal (i.p.)). Two
home-made polyethylene (PE) catheters, preﬁlled with heparin, were
connected to the pressure transducers (PowerLab 8/35 multi-channel
biological signal recording system, AD Instruments, Colorado Springs,
CO, Australia) and inserted into the right ventricle and left carotid ar-
tery, respectively, and then the right ventricular systolic pressure
(RVSP) and the mean carotid arterial pressure (mCAP) were recorded.
Next, the hearts were dissected out, divided into right ventricle (RV),
left ventricle (LV), and septum (S), and weighted, respectively. The
weight ratio of RV to LV plus S and the weight ratio of RV to body
were calculated as indexes to reﬂect RV hypertrophy.
2.4. Detection of pulmonary arterial remodeling
The upper lobe of right lung was ﬁxed in 4% paraformaldehyde over-
night, de-hydrated in increasing concentrations of ethanol, delipidated
with xylene, embedded in parafﬁn, and sectioned at 5 μm thick. After
hematoxylin and eosin (HE) staining, elastic ﬁber staining, and immuno-
staining with anti-α-SMA antibody, the structure remodeling of the pul-
monary arteries was characterized by microscopic evaluation. The
pulmonary arteries (external diameters of 25–100 μm) were chosen
randomly at a magniﬁcation of 400× and analyzed with Image-Pro Plus,
Version 6.0 (Media Cybernetics, USA). The part of α-SMA-staining
positive represented the medial layer. The percentage of pulmonary
artery wall thickness to total thickness (WA/TA%), the percentage of
wall areas to total areas (WA/TA%), and the density of nuclei in themedial
SMCs were calculated to evaluate pulmonary arterial remodeling.
2.5. Ultrastructural examination of pulmonary arteries
The lung tissues closed to the lung hilus was sectioned into small
pieces (approximately 1 × 1 × 3 mm3), ﬁxed with 2.5% glutaraldehyde
and 1% osmic acid, dehydrated with acetone, and embedded in epoxy
resin 812. And then the ﬁxed tissues were cut into ultrathin sections
with ultramicrotome and examined by a Hitachi H-7500 transmission
electron microscopy (Hitachi, Japan) after staining with uranyl acetate
and lead citrate. Five ﬁelds were obtained randomly.
2.6. Isolation and cell culture of PASMCs
Male BALB/c mice were killed by intraperitoneal injection of 10%
chloral hydrate followed by cervical dislocation that was approved by
the guideline of Wenzhou Medical College and National Institutes of
Health Standards of Animal Care. The heart and lungs were removed,
and the second to third branches of the intrapulmonary artery were
dissected in sterile phosphate buffered saline (PBS). The pulmonary
arterial tissues were digested by 0.2% collagenase type I and incubated
for 40–80 min at 37 °C. Then the cells were cultured in glucose DMEM
supplemented with 10% FBS, penicillin (100 U/mL), and streptomycin
(100 μg/mL). The smooth muscle cell was identiﬁed by microscopy
and positive staining for α-SMA.
2.7. Cell viability assay
A cell counting kit-8 (CCK-8, Dojindo, Japan) was used to detect the
effect of salidroside on cell viability in PASMCs with hypoxia exposure
or not. Mouse PASMC cells were seeded in 96 well plates (1 × 104
cells/well) and pretreated with increasing concentrations of salidroside
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trol before exposure to hypoxia (3% O2, 5% CO2, and 92% N2). After 24 h
of hypoxic exposure, CCK-8 (10 μL/well) was added to react with cells
for 2 h. The absorbancewas examined at 450 nmby amicroplate reader
(ELX800, BioTek Instruments,Winooski, VT, USA). IC50was determined
according to curvilinear regression between the salidroside concentra-
tions and cell viability index by SPSS 15.0 analysis software.
2.8. Detection of apoptosis
The cell apoptosis was qualiﬁed using the terminal deoxyribonucle-
otide transferase-mediated dUTP nick end-labeling (TUNEL) assay
(In Situ Cell Death Detection Kit, POD) according to the manufacturer's
instructions. PASMC cells or tissue sections after dewaxing and
rehydrating with xylene and ethanol were ﬁxed with 4% paraformalde-
hyde in PBS (pH 7.4) for 1 h at 25 °C, and followed by subjecting to
TUNEL assay. Diaminobenzidine (DAB) was used as the chromogen
and hematoxylin as the counterstain. Thereafter, the cover slips were
analyzed by a light microscope. The percentage of TUNEL-positive
cells was assessed in 5 randomly selected ﬁelds in each slide. For
in vitro study, mouse PASMC cells were exposed to hypoxia and treated
with salidroside (800 μmol/L), CGS-21680 (2 μmol/L), or none. Then
apoptotic cells were determined by TUNEL assay. And the activities
and cleavage of caspase 3 were analyzed with colorometric assay kits
(Bio Vision, USA) and western blotting, respectively.
2.9. Immunoﬂuorescence detection of Bax and Bcl-2 protein expressions
The frozen sections of lung tissueswereﬁxedwith acetone for 10min,
washed 3 times with PBS, blocked with 5% BSA, and incubated with the
primary antibodies, rabbit anti-MYH11 antibodies (1:100) and goat anti-
bodies against Bax and Bcl-2 (1:50). Then the sections were incubated
with secondary antibodies. The mixture of Alexa Fluor 488 Donkey
Anti-Rabbit IgG (H + L) Antibody (1:400) and 647 Donkey Anti-Goat
IgG (1:200) and the mixture of Alexa Fluor 488 Donkey Anti-Rabbit IgG
(H + L) Antibody (1:400) and 555 Donkey Anti-Goat IgG (1:200) were
used as secondary antibodies for Bax and Bcl-2 staining, respectively.
The ﬂuorescence was observed at 488, 555, and 647 nm, respectively,
with a laser scanning confocal microscope (Olympus, Tokyo, Japan) and
the ﬂuorescence intensity of Bax and Bcl-2 proteins was analyzed with
Image-Pro Plus 6.0 (Media Cybernetics, Bethesda, MD, USA). 5 ﬁelds of
5 sections were randomly selected for analysis in each group.
2.10. Western blotting analysis
Lung tissues with equal weight were homogenized with a glass ho-
mogenizer, and lysed with ultrasonic cell disruptor. PASMC cells were
lysed with ice-cold RIPA lysis buffer containing PMSF for 30 min. Then
the lysates were centrifuged at 12,000 rpm for 30 min and 15 min,
respectively, at 4 °C and the supernatant was collected. The protein
concentrations were determined by a Pierce BCA protein assay kit.
Equal amounts of proteins (40 μg) were separated with 12% SDS-
PAGE, transferred to PVDF membrane, blocked with 5% milk, and incu-
bated with speciﬁc primary rabbit antibodies against A2aR (1:200),
Bax (1:250), Bcl-2 antibody (1:250), cleaved caspase 3 (1:1000),
and cleaved caspase 9 (1:1000) at 4 °C. As for detection of cytochrome
C release, mitochondrial and cytosol pellets were isolated and
immunoblotted with antibodies against cytochrome C (1:1000) with
VDAC serving as mitochondrial marker and GAPDH as internal control.
The optical density of immunoblots was calculated with the Quantity
one-4.6.2 software (Bio-Rad Laboratories, Hercules, CA, USA).
2.11. Quantitative RT-PCR
Total RNA was extracted from mouse PASMCs with Trizol reagent.
cDNA was synthesized from 2 μg of RNA using the TIANScript ﬁrststrand cDNA synthesis kit according to the manufacturer's instructions.
Expression of A2aR mRNA was determined by quantitative RT-PCR
(qRT-PCR) with SsoAdvanced SYBR Green Supermix by the CFX96TM
Real-Time PCR system (Bio-Rad, CA, USA). The relative gene expression
was calculated by 2−ΔΔCt method [29] and normalized to GAPDH. The
sequences of the PCR primers were designed as follows: A2aR: sense:
5′-AATTGCAGACGGTCCTCTCG-3′, antisense: 5′-TGGCACCCTGCCTTTC
ATAG-3′; GAPDH: sense: 5-CTCTCTGCTCCTCCCTGTTC-3′, antisense: 5′-
CAATCTCCACTTTGCCACTGC-3′. All experiments were repeated at least
three independent times.2.12. Statistical analysis
All data were expressed as mean ± standard deviation (SD). The
comparison among more than 3 groups was analyzed by one-way
ANOVA, followed by post hoc comparison with LSD test (equal vari-
ances assumed) or Dunnett's T3 test (equal variances not assumed).
Statistical analyses were performed with SPSS for windows (SPSS
15.0, SPSS Inc., Chicago, IL, USA). A P-value b 0.05was considered statis-
tically signiﬁcant.3. Results
3.1. Salidroside attenuated chronic hypoxia-induced pulmonary arterial
hypertension and pulmonary arterial remodeling in mice
To detect the effects of salidroside on chronic hypoxia-induced PAH,
mice were exposed to chronic hypoxia for 4 weeks and treated with in-
creasing concentrations of salidroside (16, 32, and 64 mg/kg). RVSP,
mCAP, the weight ratio of RV to LV plus S, and the weight ratio of RV
to Body were calculated. As shown in Fig. 1A, RVSP, RV/LV + S, and
RV/Body were much higher in the mice exposed to hypoxia (H group)
than those exposed to normoxia (N group). However, the increase of
RVSP was inhibited by salidroside treatment in a dose-dependent
manner. Similarly, the increase of RV/LV + S and RV/Body were
inhibited by salidroside treatment and the median concentration of
salidroside (32 mg/kg) exhibited the strongest inhibitory effects. In
contrast, exposure to hypoxiawith orwithout salidroside had no effects
on mCAP in mice.
To evaluate the pulmonary arterial remodeling, we examined the
medial wall thickness and areas in pulmonary resistance vessels (exter-
nal diameters of 25–100 μm) by hematoxylin and eosin staining, immu-
nostaining forα-SMA, and elastic ﬁber staining. Exposure to hypoxia for
4 weeks caused a signiﬁcant increase in the wall thickness and areas of
pulmonary resistance vessels and the density of nuclei of SMCs in H
group compared with N group (Fig. 2A, B, C, and D). After salidroside
treatment, these increases were inhibited and salidroside in median
concentration (32 mg/kg) exerts the strongest inhibitory effect. The re-
sults suggested that salidroside inhibited hypoxia-induced pulmonary
arterial remodeling.
An examination at ultrastructure level was also performed to verify
the inhibitory effects of salidroside on chronic hypoxia-induced PAH.
Compared with the N group, endothelial of pulmonary artery in H
group was swelling, falling off, and with less of tight junction (Fig. 3).
The SMCs were abundant in cytoplasm and mitochondrion which was
also degenerated and vacuolated, and of increased vesicles. The irregu-
lar arrangement of SMCs with less ﬁlament and dense bodies was also
observed in H group. Then the pulmonary artery of the mice treated
with the median concentration of salidroside (HS32 group), which ex-
hibited the strongest inhibitory effect on chronic hypoxia-induced
PAH, was examined at ultrastructure level. In HS32 group, the endothe-
lial was ﬂat and connected well whereas the SMCs, with less organelles
such as mitochondrion and endoplasmic reticulum, had more ﬁlament
and dense bodies that were similar with the normoxia group.
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PASMCs in mice
PASMCs were the major component of the vascular media and the
main effectors of the physiological response(s) during pulmonary arte-
rial remodeling [2,25] and the excess cell growth of PASMCs was ob-
served in chronic hypoxia-induced PAH mice, which was inhibited by
salidroside. To elucidate the mechanisms, the effects of salidroside on
the PASMCs apoptosis in mice exposed to hypoxia were evaluated
with a TUNEL assay. As shown in Fig. 4A and B, the percentage of apo-
ptotic cells were signiﬁcantly decreased by hypoxia in H group com-
pared with N group. However, the salidroside treatment increased the
percentage of apoptotic cells in HS16, HS32, and HS64 groups in
which the apoptotic cells were 1.58, 2.36 and 1.63-fold to that in H
group, respectively, and all were more than that in N group. And also,
the cleavage of caspase 3 was determined by western blotting. As
shown in Fig. 4C, the cleavage of caspase 3 was decreased by hypoxia
and triggered by salidroside again. The results indicated that salidroside
enhanced the apoptosis of PASMCs and reversed chronic hypoxia-
induced apoptosis-resistance.
3.3. Salidroside modulated cell apoptosis via mitochondria dependent
pathway
As we known, mitochondria can control cell apoptosis, with mito-
chondrial depolarization activating the voltage-sensitive transition
pore to release pro-apoptotic factors. And the ultrastructural results in
the present study revealed that the mitochondria dysfunction induced
by hypoxia was rescued by salidroside. We predicted that salidroside
affected the PASMC cell apoptosis in hypoxia mice via a mitochondria
dependent pathway. Firstly, the expressions of two Bcl-2 family mem-
bers, Bax and Bcl-2, were determined by immunoﬂuorescence method.
The proteins of Bax, Bcl-2, and MYH11, as a marker of PASMCs, were
stained as red, blue, and green, respectively. As shown in Fig. 5, the
Bax expression was signiﬁcantly decreased in H group compared with
N group while the Bcl-2 expression was signiﬁcantly increased
(Fig. 5A, B, C, and D). In the salidroside treatment groups, the decrease
of Bax induced by hypoxia was inhibited by two concentrations of
salidroside (32 mg/kg and 64 mg/kg), and the increase of Bcl-2 was
reduced by 13.89%, 50.12%, and 35.67% in HS16, H32, and HS64 groups,
respectively, comparedwith H group. Furthermore, the ﬂuorescence in-
tensity ratio of Bax to Bcl-2 was evaluated to reﬂect the apoptosis level
and the results indicated that cell apoptosis was inhibited by hypoxia
and increased by salidroside treatment (Fig. 5E). Meanwhile, western
blotting analyses of Bax and Bcl-2 in lung tissue of mice were also
performed (Fig. 5F and G). Consistent with the results of immunoﬂuo-
rescence staining, the expression of Bax was modestly reduced by
hypoxia in H group compared N group (Fig. 5F) and the decrease was
reversed by the median and high concentrations of salidroside (HS32
and HS64 groups) and the expressions were even higher than that in
N group. And also salidroside inhibited chronic hypoxia-induced Bcl-2
expression and the expression levels of Bcl-2 in HS32 and H64 groups
were reduced to the same extent in N group (Fig. 5G). In addition, the
relative expression ratio of Bax to Bcl-2 was inhibited by hypoxia and
increased by salidroside treatment (Fig. 5H).
Then the release of cytochrome C and the cleavage of caspase 9,
down-regulators of Bax/Bcl-2 in themitochondria dependent apoptosis
pathway, were determined. As shown in Fig. 6, hypoxia inhibited the
release of cytochrome C from mitochondria to cytoplasm that was re-
versed by salidroside treatment (Fig. 6A, B, and C). The cleaved caspase
9 was analyzed by western blotting and the results indicated that theFig. 1. Salidroside inhibited chronic hypoxia-induced PAH in mice. A) Mice were exposed t
(16 mg/kg, 32 mg/kg, and 64 mg/kg, named as HS16, HS32, HS64, respectively) for 4 week
pictures of RVSP waves in the N, H, HS16, HS32, and HS64 groups. ## p b 0.01 vs. the N groupcleavage of caspase 9 was decreased by hypoxia and enhanced by
salidroside (Fig. 6D). All the clues above suggested that a mitochondria
dependent apoptosis axis, Bax/Bcl-2-cytochromeC-caspase 9-caspase 3,
was involved in salidroside regulation of cell apoptosis in hypoxia-
induced PAH in mice.
3.4. Salidroside modulated cell apoptosis in mouse PASMCs after chronic
hypoxia exposure in vitro
The animal studies above showed that salidroside attenuated chron-
ic hypoxia-induced PAH andpulmonary arterial remodeling via enhanc-
ing cell apoptosis in PASMCs in mice. Next, we aimed to verify the
conclusions in mouse PASMCs. Firstly, PAMSCs were isolated from
mouse, as shown in Figure S1, the conﬂuent primary cells retained a
good spindle shape under a phase contrastmicroscope. However, unlike
the primary cells, passages of PASMCs presented an irregular shape.
Then PASMCs were examined by immunoﬂuorescence staining for α-
SMA and immunochemical staining for myoﬁlament. Both methods
identiﬁed the mouse PASMCs and manifested the cell purity of more
than 95%. Secondly, the effects of salidroside on hypoxia-induced cell via-
bility in PASMCswere analyzed by CCK-8 assay. PASMCswere exposed to
hypoxia and treated with increasing concentrations of salidroside (0.8, 8,
80, and 800 μmol/L), and the treatment of CGS-21680 (2 μmol/L), an A2aR
agonist, served as a positive control. Salidroside inhibited chronic
hypoxia-induced cell growth in a dose-dependentmanner and the inhib-
itory effect of salidroside in the dose of 800 μmol/L was similar with that
of CGS (Fig. 7A). The IC50 of salidroside in inhibiting cell growth induced
by hypoxia in PASMCs was 16 μmol/L. The attenuation of cell growth
might be resulted from the induction of cell apoptosis. Then, a TUNEL
assay was performed to determine the effects of salidroside on hypoxia-
decreased cell apoptosis in PASMCs. The cells were exposed to hypoxia
and treated with a high dose of salidroside (800 μmol/L) or CGS. Hypoxia
decreased signiﬁcantly the apoptosis level in H group compared with N
group while there was a marked increase of cell apoptosis in the HS800
and HCGS groups compared with H group, which were also much higher
than that in N group (Fig. 7B and C). Next, the activities and cleavage of
caspase 3 were also detected to indicate cell apoptosis. The results sug-
gested that hypoxia decreased caspase 3 activities and cleavage while
salidroside or CGS enhanced the activities and cleavage of caspase 3
under hypoxia conditions (Fig. 7D and E). Finally, the mitochondria de-
pendent apoptosis factors, Bax, Bcl-2, and caspase 9 were examined by
western blotting. After hypoxia exposure, the Bax expression was
inhibited and the inhibition was reversed by salidroside or CGS
(Fig. 8A). And the expression ratio of Bax to Bcl-2 was also inhibited by
hypoxia while salidroside attenuated the inhibition, consistent with re-
sults in vivo, although discrepancy existed in Bcl-2 expression after
salidroside treatment thatmight bedue to thedifference of hypoxia expo-
sure duration (Fig. 8B and C). Analyses of the activities and cleavage of
caspase 9 demonstrated that they were inhibited by hypoxia and en-
hanced by salidroside or CGS (Fig. 8D and E). All the results indicated
that salidroside reversed hypoxia induced PASMC apoptosis resistance
via enhancing mitochondria dependent apoptosis in vitro.
3.5. Salidroside increased A2aR protein and mRNA expressions in lung
tissues in hypoxia-PAH mice and mouse PASMCs in vitro under hypoxia
conditions
Previous evidence indicated adenosine A2a receptor (A2aR) is a dom-
inant type in pulmonary artery and has a role in protective effects in the
development of PAH and pulmonary arterial remodeling in mice [26].
So we tested the effects of salidroside on A2aR protein and mRNAo normoxia (N), hypoxia (H), or hypoxia with increasing concentrations of salidroside
s. RVSP, mCAP, RV/(LV + S), and RV/Body weight were calculated. B) Representative
; ** p b 0.01 vs. the H group; n= 8.
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Fig. 3. Effects of salidroside on PAH at ultrastructure level. The ultrathin sections of lung tissues in N, H, and HS32 groups were observed under a Hitachi H-7500 transmission electron
microscopy. White arrow: cell nucleus; Red arrow: mitochondria; Blue arrow: endoplasmic reticulum; Yellow arrow: basement membrane; Orange arrow: dense body.
159X. Huang et al. / Journal of Molecular and Cellular Cardiology 82 (2015) 153–166expressions in vivo and in vitro after hypoxia exposure. A2aR protein
expression in lung tissues in hypoxia-PAH mice was analyzed by
western blotting and the results revealed hypoxia increased A2aR ex-
pression in H group compared with N group (Fig. 8F). Salidroside
treatment enhanced A2aR expression further in HS16 and HS32
groups but not in HS64 group and the median concentration ofFig. 2. Salidroside reduced pulmonary arterial remodeling. A) Percentages of wall thicknes
D) Representative photomicrograph of pulmonary arterial remodeling indicated by HE staini
lung tissues of mice. Scale bar: upper, 12.5 μm; lower, 50 μm. ## p b 0.01 vs. the N group; ** psalidroside (32 mg/kg) exhibited the strongest enhancement
(Fig. 8F). Linear regression analysis revealed a correlation between
A2aR expressions and salidroside concentrations in H, HS16,
and HS32 groups (r2 = 0.784, p b 0.001, Figure S2). The HS64
group was excluded because this high dose of salidroside might ex-
ceed the optimal concentrations, evidenced by the phenotypes and wall areas and the density of nuclei of SMCs in different treatment groups. B, C,
ng (B), immunostaining with anti-α-SMA antibody (C), and elastic ﬁber staining (D) in
b 0.01 vs. the H group; n= 8.
Fig. 4. Effects of salidroside and hypoxia on the apoptosis of PASMCs in mice. A and B). Lung tissue sections in each group were stained with TUNEL reagent. The apoptotic PASMCs were
quantiﬁedwith Image-Pro Plus, Version 6.0. C). Lung tissueswere detectedwithwestern blottingwith antibody against cleaved caspase 3withβ-actin as internal control. Scale bar: 50 μm.
## p b 0.01 vs. the N group; ** p b 0.01 vs. the H group; n= 3.
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Then A2aR protein and mRNA expressions in mouse PASMCs treated
with salidroside or CGS under hypoxia conditions were also deter-
mined by western blotting and quantitative RT-PCR. The results
demonstrated that hypoxia elevated A2aR protein andmRNA expres-
sions and salidroside or CGS treatment increased the expressions
further (Fig. 8G and H). Regarding the similar effects of salidroside
and CGS on cell apoptosis and A2aR expressions, we speculated thatsalidroside enhanced cell apoptosis in PASMCs under hypoxia condi-
tions possibly through up-regulating A2aR expression.
4. Discussion
In the present study, we addressed that salidroside could attenuate
chronic hypoxia-induced PAH. Chronic hypoxia exposure led to an
increase of RVSP, RV/LV + S, RV/Body, and media thickening of
Fig. 5. Effects of salidroside on Bax and Bcl-2 expressions in PASMCs and lung tissues inmice. A and B) The expressions of Bax (A), Bcl-2 (B), andMYH11 in PASMCs inmice were analyzed
by immunoﬂuorescence staining. Bax, and Bcl-2 proteinswere stained as red and blue, respectively, andMYH11was stained as green to indicate PASMCs. Scale bar: 50 μm. C, D, and E) The
ﬂuorescence intensity of Bax and Bcl-2was quantiﬁed and theﬂuorescence ratio of Bax to Bcl-2was calculated. F andG) Bax and Bcl-2 protein expressions in lung tissueswere determined
bywestern blottingwith GAPDHas an internal control. H) And theprotein expression ratios of Bax to Bcl-2were also calculated. # p b 0.05, ## p b 0.01 vs. theN group; * p b 0.05, **p b 0.01
vs. the H group; n= 5.
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Fig. 6. Salidroside enhanced cytochrome C release and caspase 9 cleavage in lung tissues of mice under hypoxia. A, B, and C) The expressions of cytochrome C in mitochondrial (A) and
cytosol pellets (B) of lung tissueofmice treatedwith salidrosideunder hypoxiawere analyzedbywestern blottingwith antibodies against cytochromeCwithVDCAasmitochondriamark-
er and GAPDH as internal control. The relative levels of cytochrome C inmitochondria to that in cytoplasmwere calculated. D) Cleaved caspase 9 in the lung tissues was analyzed bywest-
ern blottingwith cleaved caspase 9 antibody and the relative levels of cleaved caspase 9were quantiﬁed. # p b 0.05, ## p b 0.01 vs. the N group; * p b 0.05, ** p b 0.01 vs. theH group; n=5.
162 X. Huang et al. / Journal of Molecular and Cellular Cardiology 82 (2015) 153–166pulmonary arterioles in mice. However, the increase could be inhibited
by the treatment of salidroside. Furthermore, through the in vivo and
in vitro studies, we demonstrated that salidroside might function byreversing hypoxia induced apoptosis resistance partially via enhancing
A2aR relatedmitochondria-dependent apoptosis. The novel information
revealed the effects of salidroside on PAH and partially clariﬁed the
Fig. 7. Effects of hypoxia, salidroside, and CGS-21680 on cell viability and apoptosis of PASMCs in vitro. A)Mouse PASMCs cells were exposed to hypoxia and treated with increasing con-
centrations of salidroside (0–800 μmol/L) or CGS-21680 (2 μmol/L). Cell viabilitywas analyzedby a CCK-8 assay. B) PASMC cellswere treatedwith salidroside or CGS-21680under hypoxia
conditions. A TUNEL assay was used to analyze cell apoptosis in PASMCs. C) The apoptotic cells were quantiﬁed by Image-Pro Plus, Version 6.0. D, E) Activities and cleavage of caspase 3 in
PASMC cells treated as in (B)were analyzed by colorimetric assay andwestern blotting. Scale bar: 50 μm. ## p b 0.01 vs. the N group; ** p b 0.01 vs. the H group; && p b 0.01 vs. the HS800
group; n= 6.
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monary arterial remodeling in PAH mice.
PAH is characterized by increased pulmonary vascular resistance
resulting in progressive right ventricular hypertrophy (RVH) and even-
tual right heart failure. The key pathological change responsible for in-
creased pulmonary vascular resistance in all categories of PAH is small
pulmonary arterial remodeling that is attributed primarily to excessive
proliferation and impaired apoptosis of PASMCs [27]. Current therapies
for PAH may improve hemodynamics but often fail to yield long-term
beneﬁts and improve mortality [28,29]. The limited efﬁcacy of these
therapies is usually because theirmechanism of action ismainly pulmo-
nary vasodilation. Salidroside, a pharmacologically active ingredient pu-
riﬁed from Rhodiola, possesses multiple pharmacological activities.
Recent studies indicate that salidroside can rescue mitochondria dys-
function induced by stimuli in human umbilical vein endothelial cells
(HUVECs) [23] and block platelet-derived growth factor-BB induced
proliferation of PASMCs [24], suggesting that salidroside may, via
rebalancing cell proliferation and mitochondria-dependent apoptosis
of pulmonary artery cells, exert protective effects against PAH. Howev-
er, speciﬁc function of salidroside in PAH has not been investigatedsystematically and the underlyingmechanisms are not explored. To ad-
dress the effects of salidroside on PAH, we established a mice model of
chronic hypoxia-induced PAH, demonstrated by the increase of RVSR,
RV/LV + S, RV/Body, and media thickening of pulmonary arterioles.
After salidroside injection, the pathological changes were attenuated
and a dose of 32 mg/kg exerted the strongest inhibitory effects on
PAH. As pulmonary arterial remodeling, a key pathological change re-
sponsible for PAH, is attributed primarily to excessive proliferation
and impaired apoptosis of PASMCs [27], here we investigated if
salidroside affected pulmonary arterial remodeling by regulating cell
apoptosis. The TUNEL assay and western analysis of the cleavage of cas-
pase 3 suggested that salidroside reversed the suppression of apoptosis
induced by hypoxia. The changes of mitochondria at ultrastructural
level and cell apoptosis before and after salidroside treatment under
hypoxia conditions indicated that the mitochondria dependent apopto-
sis pathwaymight be involved in the regulatory process. Previous stud-
ies reported that the pro-apoptotic factor, Bax, enhances cytochrome C
release and activates caspase 9 and 3 to execute apoptotic program
while Bcl-2, an anti-apoptosis molecule, inhibits Bax activation and cy-
tochrome C release to suppress the apoptosis [13–15]. In our study,
Fig. 8. Salidroside triggered amitochondria dependent apoptosis inmouse PASMCs and up-regulated A2aR expression. A, B, and C)Mouse PASMCs cells were exposed to normoxia (N), or
hypoxia (H), or hypoxia with salidroside (HS800) or hypoxia with CGS-21680 (HCGS). The expressions of Bax (A) and Bcl-2 (B) were analyzed with western blotting and the protein ex-
pression ratio of Bax to Bcl-2 was evaluated (C). D and E) Activities and cleavage of caspase 9 were also determined. F) Mice were treated with normoxia (N), or hypoxia (H), or hypoxia
with salidroside (HS16, HS32, and HS64). A2aR expression in each group was examined by western blotting. B, C) A2aR protein and mRNA expressions in the PASMCs in A were also ex-
amined by western blotting and qRT-PCR, respectively. # p b 0.05, ## p b 0.01 vs. the N group; * p b 0.05, ** p b 0.01 vs. the H group; & p b 0.05, && p b 0.01 vs. the HS800 group; n= 6.
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165X. Huang et al. / Journal of Molecular and Cellular Cardiology 82 (2015) 153–166the mitochondria dependent apoptotic factors, Bax, Bcl-2, cytochrome
C, and caspase 9 were determined. The immunoﬂuorescence staining
results in PASMCs in mice demonstrated that hypoxia inhibited Bax ex-
pression and induced Bcl-2 expression; however, both of which were
reversed by salidroside and the conclusionswere veriﬁed by the follow-
ingwestern blot analysis of lung tissues inmice. Next, the cytochrome C
release in lung tissue in mice was determined and we found that
salidroside reversed hypoxia-induced inhibition of cytochrome C re-
lease from mitochondria into cytoplasm. Finally, western blot analysis
revealed that the cleavage of caspase 9 was inhibited by hypoxia and
enhanced by salidroside. An in vitro study was also performed with
PASMCs isolated from mouse to conﬁrm the involvement of mitochon-
dria dependent apoptosis in salidroside regulation of PASMCs after
hypoxia exposure. Both the results in vivo and in vitro indicated that
salidroside exhibits protective effects against PAH partially via inducing
a mitochondria dependent apoptosis of PASMCs.
Four different adenosine receptor subtypes, A1, A2a, A2b, and A3,
which signal mainly through coupling with G proteins, mediate the bi-
ological effects of adenosine [30]. Of the four adenosine receptor sub-
types, A2aR is dominatingly expressed in pulmonary artery and
experimental evidence indicates that extracellular adenosine acting at
A2aR represents the protective effects on the development of PAH and
pulmonary arterial remodeling in mice [26]. The adenosine levels are
higher in the pulmonary because the SMCs can synthesize a substantial
amount of adenosine [31,32]. However, patients with PAH have lower
adenosine levels in the pulmonary [26,31]. In our study, an increased
A2aR expression was determined in lung tissue in mice and mouse
PASMCs under hypoxia condition, indicating that a potential negative
feedback between adenosine and A2aR exists in PAH. Furthermore,
salidroside treatment elevated more increased A2aR expression,
suggesting that salidroside exerted effects on PAH via A2aR. It has also
been reported that A2aR has a role in the apoptotic effects via the Bax
and Bcl-2 pathway [33]. Combining the clues and effects of salidroside
on cell apoptosis in PAMSCs in the present study, we proposed that
salidroside targeted A2aR and then resulted in modulation of PASMC
apoptosis via a mitochondria-dependent pathway. That would explain
the similar effects of salidroside and CGS, an A2aR agonist on cell
apoptosis in PASMCs exposed to hypoxia. The regulatory mechanisms
of A2aR expression induced by salidroside under hypoxia conditions
are still unclear. Based on the previous reports that NF-κB activation
can upregulate A2aR expression and adenosine can activate A2aR
which then results in NF-κB activation [34,35], we speculate that
salidroside, in hypoxia PASMCs, activates A2aR and the activation of
A2aR elevates NF-κB activation, which in turn upregulates A2aR expres-
sion.Wewill perform further studies to clarify the detailedmechanisms
in the future.
In summary, salidroside is effective in inhibiting chronic hypoxia-
induced PAH and pulmonary arterial remodeling partially via the
mechanism of enhancing A2aR related mitochondria-dependent
apoptosis. This will provide a signiﬁcant insight of the protective effects
of salidroside in PAH and the underlying mechanisms may become a
theoretical basis for the use of salidroside in themanagement of clinical
hypoxic pulmonary hypertension.Conﬂict of interest
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